Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies


Our achievements would not be possible without the outstanding team that make up Shield Therapeutics’ staff, management and board of directors.

Non-Executive Director

Peter Llewellyn-Davies

Peter is a strategic CFO with an over 25 year track record in international M&A deals, company turnarounds, licensing transactions and financing activities with particular experience in chemical and healthcare industries. Peter was CFO of Medigene AG between 2012 and 2016 and supported the turnaround process by outlicensing marketed and legacy products and enhancing shareholder value with a large international investor base. Prior to that he was CFO of Wilex AG, having orchestrated their IPO in 2006 to fund a later stage pipeline and conclude subsequent partnering deals and acquisitions. Peter is a founder of Accellerate Partners, focused on executing change and supporting private and listed companies and advising venture capital and private equity firms. Peter read business management, banking, marketing and controlling in London, St. Gallen and Munich, and has a certificate in business studies from the University of London. Peter was nominated for appointment to the Board pursuant to the Relationship Agreement.

Back to team